drugset / Trial / NCT00002297

A Study of Isoprinosine in Patients With Lymph Node Disease

NCT00002297

Double-blindTreatment

Summary

The objectives of this study are to determine the effects of isoprinosine in patients diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will include: Signs and symptoms: * Lymphadenopathy. * Fever. * Weight loss. * Occurrence of opportunistic infections. Cell-mediated immune system parameters: * T-helper cell (OKT4) numbers and proportions. * T-suppressor cell (OKT8) numbers and proportions. * Natural killer (NK) cell activity. * Lymphocyte blastogenic response to phytohemagglutinin (PHA). * Lymphocyte blastogenic response to pokeweed mitogen (PWM). * Immunoglobulin (IgG, IgA, IgM, IgE, IgD) profile. * Circulating immune complexes. Infections characteristically associated with AIDS, such as Candida albicans, Pneumocystis carinii pneumonia, Cytomegalovirus, Herpes simplex, Cryptococcus, Histoplasma, Toxoplasma, Cryptosporidium, Mycobacterium avium- intracellulare, Legionella, and Isospora. Safety parameters: * Blood chemistry including serum uric acid (PurposeA-12). * Complete blood count (CBC). * Platelet count.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Inosine pranobex Unknown